Journal Mobile Options
Table of Contents
Vol. 4, No. 2, 2011
Issue release date: July 2011
J Nutrigenet Nutrigenomics 2011;4:99–109
(DOI:10.1159/000327768)

The Basis of Differential Responses to Folic Acid Supplementation

Cotlarciuc I. · Andrew T. · Dew T. · Clement G. · Gill R. · Surdulescu G. · Sherwood R. · Ahmadi K.R.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background/Aims: Elevated levels of total homocysteine (tHcy) are associated with an increased risk of many common diseases. Supplementation with folic acid has been shown to significantly reduce tHcy levels. We used the classical twin model to partition the variability in changes in plasma tHcy levels through folic acid supplementation into genetic, environmental, and confounding epidemiological factors. Methods: We carried out an intervention study of folic acid using 101 healthy, female, identical and non-identical twins aged 50–80 years. Each twin was administered folic acid (0.8 mg/day) for 6 weeks. Total plasma folate, cobalamin and tHcy were measured at both baseline and after dosing. We calculated the heritability and tested for associations between the MTHFR C677T functional variant and response to folic acid supplementation. Results: Supplementation with folic acid led to a significant reduction in tHcy levels. The mean tHcy changed from 12.14 to 10.42 µmol/l after supplementation (p < 10–5). Moreover, the change in tHcy levels was highly heritable (64%), not associated with the C677T functional variant at MTHFR and not confounded by age, BMI or diet. Conclusions: Our results highlight the need to identify genetic factors associated with biomarkers of response to folate supplementation.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Wald D, Law M, Morris J: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202–1206.
  2. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD: Homocysteine and stroke: evidence on a causal link from Mendelian randomisation. Lancet 2005;365:224–232.
  3. Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, Weir DG, Scott JM: Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995;345:149–151.
  4. den Heijer M, Lewington S, Clarke R: Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005;3:292–299.
  5. McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE, Hannan MT, Cupples LA, Kiel DP: Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004;350:2042–2049.
  6. van Meurs JBJ, Dhonukshe-Rutten RAM, Pluijm SMF, van der Klift M, de Jonge R, Lindemans J, de Groot LCPGM, Hofman A, Witteman JCM, van Leeuwen JPTM, Breteler MMB, Lips P, Pols HAP, Uitterlinden AG: Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004;350:2033–2041.
  7. Boushey C, Beresford S, Omenn G, Motulsky A: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049–1057.
  8. van Dijk RAJM, Rauwerda JA, Steyn M, Twisk JWR, Stehouwer CDA: Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol 2001;21:2072–2079.
  9. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M: Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565–575.
  10. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr, Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators: Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567–1577.
  11. B-Vitamin Treatment Trialists’ Collaboration: Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J 2006;151:282–287.
  12. Bazzano LA, Reynolds K, Holder KN, He J: Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 2006;296:2720–2726.
  13. Saposnik G, et al: Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke 2009;40:1365–1372.
  14. Cesari M, Burlina AB, Narkiewicz K, Sartori MT, Sacchetto A, Rossi GP: Are fasting plasma homocyst(e)ine levels heritable? A study of normotensive twins. J Investig Med 2000;48:351–358.
  15. Jee S, Song K, Shim W, Kim H, Suh I, Park J, Won S, Beaty T: Major gene evidence after MTHFR-segregation analysis of serum homocysteine in families of patients undergoing coronary arteriography. Hum Genet 2002;111:128–135.
  16. Kluijtmans LAJ, Young IS, Boreham CA, Murray L, McMaster D, McNulty H, Strain JJ, McPartlin J, Scott JM, Whitehead AS: Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 2003;101:2483–2488.
  17. den Heijer M, Graafsma S, Lee S, van Landeghem B, Kluijtmans L, Verhoef P, Beaty T, Blom H: Homocysteine levels – before and after methionine loading – in 51 Dutch families. Eur J Hum Genet 2005;13:753–762.
  18. Bathum L, Petersen I, Christiansen L, Konieczna A, Sorensen TIA, Kyvik KO: Genetic and environmental influences on plasma homocysteine: results from a Danish twin study. Clin Chem 2007;53:971–979.
  19. Siva A, Lange MD, Clayton D, Monteith S, Spector T, Brown MJ: The heritability of plasma homocysteine, and the influence of genetic variation in the homocysteine methylation pathway. Q J Med 2007;100:495–499.
  20. Spector TD, Williams FM: The UK Adult Twin Registry (TwinsUK). Twin Res Hum Genet 2006;9:899–906.
  21. Neale MC, Maes HM: Methodology for Genetic Studies of Twins and Families. Dordrecht, Kluwer Academic Publishers, 1992, pp 1–31.
  22. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM: Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998;158:862–867.
  23. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049–1057.
  24. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG: Prospective study of serum total homocysteine concentrations and risk of stroke in middle-aged British men. Lancet 1995;346:1395–1398.
  25. Mayer EL, Jacobsen DW, Robinson K: Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517–527.
  26. Wald DS, Bishop L, Wald NJ, Law M, Hennessy E, Weir D, McPartlin J, Scott J.: Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med 2001;161:695–700.
  27. Olthof MR, Bots ML, Katan MB, Verhoef P: Effect of folic acid and betaine supplementation on flow-mediated dilation: a randomized, controlled study in healthy volunteers. PLoS Clin Trials 2006;1:e10.
  28. Shelnutt KP, Kauwell GP, Chapman CM, Gregory JF 3rd, Maneval DR, Browdy AA, Theriaque DW, Bailey LB: Folate status response to controlled folate intake is affected by the methylenetetrahydrofolate reductase 677C→T polymorphism in young women. J Nutr 2003;133:4107–4111.
  29. Guinotte CL, Burns MG, Axume JA, Hata H, Urrutia TF, Alamilla A, McCabe D, Singgih A, Cogger EA, Caudill MA: Methylenetetrahydrofolate reductase 677C→T variant modulates folate status response to controlled folate intakes in young women. J Nutr 2003;133:1272–1280.
  30. Liu CS, Chiang HC, Chen HW: Methylenetetrahydrofolate reductase polymorphism determines the plasma homocysteine-lowering effect of large-dose folic acid supplementation in patients with cardiovascular disease. Nutrition 2004;20:974–978.
  31. Paré G, Chasman DI, Parker AN, Zee RR, Mälarstig A, Seedorf U, Collins R, Watkins H, Hamsten A, Miletich JP, Ridker PM: Novel associations of CPS1, MUT, NOX4, and DPEP1 with plasma homocysteine in a healthy population: a genome-wide evaluation of 13974 participants in the Women’s Genome Health Study. Circ Cardiovasc Genet 2009;2:142–150.
  32. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M: Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565–575.
  33. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr, Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators: Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567–1577.
  34. Bazzano LA, Reynolds K, Holder KN, He J: Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 2006;296:2720–2726.
  35. Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E, Heart Outcomes Prevention Evaluation 2 Investigators: Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke 2009;40:1365–1372.
  36. Andrew TM, Hart DJ, Snieder H: Are twins and singletons comparable? A study of disease-related and lifestyle characteristics in adult women. Twin Res 2001;4:464–477.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50